Nanao Terada
Overview
Explore the profile of Nanao Terada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tambo Y, Sone T, Nishi K, Shibata K, Kita T, Araya T, et al.
Lung Cancer
. 2025 Feb;
201:108422.
PMID: 39952082
Introduction: Use of pembrolizumab as first-line treatment in patients with non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥ 50 % was approved in Japan 5 years...
2.
Terada N, Koba H, Nanjo S, Kimura H, Nishiyama A, Yoneda T, et al.
Transl Lung Cancer Res
. 2024 Dec;
13(11):3067-3082.
PMID: 39670006
Background: The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is widely used as a first-line treatment for -mutated non-small cell lung cancer (NSCLC). However, there is...
3.
The lung as a site for the generation of anti-MDA5 antibody in clinically amyopathic dermatomyositis
Hara R, Watanabe S, Terada N, Kase K, Muto A, Hamaguchi Y, et al.
Rheumatology (Oxford)
. 2024 Jun;
63(12):e336-e338.
PMID: 38833678
No abstract available.
4.
Yamamura K, Hara J, Watanabe S, Kobayashi T, Kase K, Takeda Y, et al.
J Thorac Dis
. 2024 Apr;
16(3):2159-2166.
PMID: 38617783
Cough is a common and important sign/symptom in patients with idiopathic pulmonary fibrosis (IPF). However, there have been few reports focusing on cough, and the exact mechanisms for cough in...
5.
Koba H, Yoneda T, Morita H, Kimura H, Murase Y, Terada N, et al.
Thorac Cancer
. 2024 Feb;
15(8):661-666.
PMID: 38323355
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is crucial for patients with lung cancer harboring EGFR mutations. However, almost all patients experience disease progression, regardless of their response...
6.
Tsukida S, Watanabe S, Hongo M, Murase Y, Yamamoto Y, Kase K, et al.
Chest
. 2023 Sep;
164(3):e71-e74.
PMID: 37689476
A 71-year-old woman sought treatment for a nonproductive cough. The patient had experienced no episodes of hemoptysis or shortness of breath. Her illness history included lumbago and dry mouth. The...
7.
Yoneda T, Sone T, Koba H, Shibata K, Suzuki J, Tani M, et al.
Clin Lung Cancer
. 2022 May;
23(6):467-476.
PMID: 35618628
Background: Immune checkpoint inhibitor (ICI) monotherapy is more effective than cytotoxic chemotherapy in improving overall survival (OS) among patients with advanced-stage non-small cell lung cancer (NSCLC). Recently, chemotherapy combined with...
8.
Shimizu T, Watanabe S, Yoneda T, Kinoshita M, Terada N, Kobayashi T, et al.
Allergol Int
. 2021 Nov;
71(2):251-253.
PMID: 34772608
No abstract available.
9.
Matsuoka H, Araya T, Kita T, Terada N, Yamamura K, Nishikawa S, et al.
J Cancer
. 2021 Jun;
12(15):4478-4487.
PMID: 34149911
Cancer cells usually escape tumor-reactive T-cell responses using immune checkpoint proteins, such as programmed death protein-1 (PD-1) and its ligand, programmed death ligand-1 (PD-L1). These proteins can be blocked by...
10.
Yamamura K, Hara J, Kobayashi T, Ohkura N, Abo M, Akasaki K, et al.
J Med Invest
. 2019 May;
66(1.2):157-164.
PMID: 31064931
Background Asthma-COPD overlap (ACO) is a disease that shares clinical features of both asthma and COPD. The purpose of this study is to investigate the prevalence and clinical features of...